Table 1 Baseline characteristics of study patients
TACE + Sorafenib | TACE + Placebo | |||
|---|---|---|---|---|
n = 24 | n = 26 | |||
Age (years) median (min-max) | 58.5 | (44.0-66.0) | 58.0 | (43.0-69.0) |
BMI (kg/m2) median (min-max) | 27.5 | (20.2-40.6) | 26.3 | (21.0-37.9) |
Biopsy proven n (%) | ||||
yes | 8 | (33.3%) | 6 | (23.1%) |
no | 16 | (66.7%) | 20 | (76.9%) |
Child pugh stage n (%) | ||||
A | 14 | (58.3%) | 20 | (76.9%) |
B | 9 | (37.5%) | 6 | (23.1%) |
C | 1 | (4.2%) | - | |
Karnofsky index n (%) | ||||
80 | 6 | (25.0%) | 4 | (15.4%) |
90 | 10 | (41.6%) | 16 | (61.5%) |
100 | 8 | (33.3%) | 6 | (23.1%) |
Underlying liver disease n (%) | ||||
Viral hepatitis | ||||
B | 3 | (12.5%) | 3 | (11.5%) |
C | 11 | (45.8%) | 7 | (26.9%) |
alcoholic | 7 | (29.1%) | 11 | (42.3%) |
other | 3 | (12.5%) | 5 | (19.2%) |
MELD score at listing median (min-max) | ||||
labMELD score | 11 | (6–15) | 11 | (6–37) |
exceptional MELD score | 27.5 | (27.5-40.1) | 25.2 | (21.9-40.1) |
AFP (IU/ml) median (min-max) | ||||
start of study | 13.2 | (1.2 – 2.961) | 9.8 | (1.3 – 225) |
end of study | 6.2 | (1.0 – 1.788) | 9.4 | (2.0 – 362) |